Monopar Therapeutics Inc. (MNPR) News
Track canonical SquawkNews coverage tagged to MNPR, Monopar Therapeutics Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 3 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Monopar Says FDA Grants Rare Pediatric Disease Designation To ALXN1840, Late-Stage Candidate For Treatment Of Wilson Disease
Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ: MNPR ), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that the U.S. Foo
REGULATION | Jun 30, 2026, 12:03 PM UTC
M
HC Wainwright & Co. Reiterates Buy on Monopar Therapeutics, Maintains $105 Price Target
HC Wainwright maintains Buy rating on Monopar Therapeutics.
EQUITY | Jun 29, 2026, 10:26 AM UTC
M
12 Health Care Stocks Move
Twelve health care stocks are moving in Tuesday's intraday session, with Aditxt and Atlantic International leading the gainers and Trinity Biotech and Tenon Medical leading the losers
EQUITY | Jun 23, 2026, 05:09 PM UTC